Patritumab Deruxtecan Biologics License Application for Patients With Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

On May 29, 2025 Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, reported that the Biologics License Application (BLA) seeking accelerated approval in the U.S. for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn (Press release, Merck & Co, MAY 29, 2025, View Source [SID1234653490]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance, as well as discussions with the U.S. Food and Drug Administration. The decision is unrelated to the Complete Response Letter that was received in June 2024 and outlined findings pertaining to an inspection of a third-party manufacturing facility.

Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck

Results from the HERTHENA-Lung02 Phase 3 trial, including previously reported statistically significant progression-free survival (PFS) along with topline OS results, will be presented during an oral presentation (#8506) at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (#ASCO25) Annual Meeting on Sunday, June 1, 2025.

HERTHENA-Lung02 is evaluating patritumab deruxtecan monotherapy versus doublet chemotherapy, consisting of platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy, in patients with EGFR-mutated (exon 19 deletion or L858R mutated) advanced NSCLC after disease progression with a third generation EGFR tyrosine kinase inhibitor (TKI) treatment. Patients achieving tumor response will continue to receive patritumab deruxtecan or chemotherapy until disease progression, per investigator assessment.

"EGFR-mutated non-small cell lung cancer has proven to be difficult-to-treat in the second-line metastatic setting and beyond," said Ken Takeshita, MD, global head, R&D, Daiichi Sankyo. "While we are disappointed with the overall survival results of HERTHENA-Lung02, we are conducting further biomarker analyses to better identify patients that may benefit from patritumab deruxtecan to guide our continued development in lung cancer. We remain confident in the broad development program of this HER3 directed antibody drug conjugate, which currently includes multiple clinical trials across 15 types of cancer."

"Lung cancer is one of the leading causes of cancer-related deaths worldwide and these results are a reminder of how challenging it can be to treat these patients with EGFR-mutated non-small cell lung cancer in the second and later line settings," said Eliav Barr, MD, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "We would like to thank the patients, their families, and investigators for their participation in this study."

The safety profile seen in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer clinical trials, with no new safety signals identified.

About HERTHENA-Lung01

HERTHENA-Lung01 is a global, multicenter, open-label, two-arm Phase 2 trial evaluating the safety and efficacy of patritumab deruxtecan in patients with EGFR-mutated locally advanced or metastatic NSCLC following disease progression with an EGFR TKI and platinum-based chemotherapy. Patients were randomized 1:1 to receive 5.6 mg/kg (n=225) or an uptitration regimen (n=50). The uptitration arm was discontinued as the dose of 5.6 mg/kg of patritumab deruxtecan was selected following a risk-benefit analysis conducted from a separate Phase 1 trial assessing the doses in a similar patient population.

The primary endpoint of HERTHENA-Lung01 was objective response rate (ORR) as assessed by blinded independent central review (BICR). Secondary endpoints included duration of response, PFS, disease control rate, and time to response – all assessed by both BICR and investigator assessment – as well as investigator-assessed ORR, OS, safety and tolerability. The ORR data and additional results for key secondary endpoints of HERTHENA-Lung01 were published in the Journal of Clinical Oncology in September 2023.

HERTHENA-Lung01 enrolled 277 patients in Asia, Europe, North America and Oceania. For more information about the trial, visit ClinicalTrials.gov.

About HERTHENA-Lung02

HERTHENA-Lung02 is a global, multicenter, open-label, Phase 3 trial evaluating the efficacy and safety of patritumab deruxtecan (5.6 mg/kg every three weeks) monotherapy versus four cycles of doublet chemotherapy) pemetrexed and platinum chemotherapy) in patients with metastatic or locally advanced NSCLC with an EGFR-activating mutation (exon 19 deletion or L858R) after failure of third-generation (e.g., osimertinib, lazertinib, aumolertinib, alflutinib) EGFR TKI therapy. Patients in the chemotherapy arm without disease progression after four cycles of pemetrexed and platinum chemotherapy are able to continue treatment with maintenance pemetrexed with no restriction on the number of cycles.

The primary endpoint of HERTHENA-Lung02 is PFS as assessed by BICR. Secondary endpoints included OS, ORR, duration of response, clinical benefit rate, time to response, disease control rate, and safety. Patients enrolled in the study underwent brain imaging to allow for assessment of intracranial endpoints, including intracranial PFS as assessed by BICR.

HERTHENA-Lung02 enrolled 586 patients in Asia, Europe, North America and Oceania. For more information about the trial, visit ClinicalTrials.gov.

About EGFR-Mutated Non-Small Cell Lung Cancer

Nearly 2.5 million lung cancer cases were diagnosed globally in 2022. Lung cancer is the most common cancer and the leading cause of cancer-related deaths worldwide.9 NSCLC accounts for about 87% of all lung cancers1. Approximately 10% to 15% of patients with NSCLC in the U.S. and Europe, and 30% to 40% of patients in Asia have an EGFR mutation.3,4

NSCLC is diagnosed at an advanced stage in up to 70% of patients.2 For patients with tumors that have an EGFR mutation, the established first-line treatment in the metastatic setting includes EGFR-directed therapy with or without platinum-based chemotherapy.While these therapies have improved outcomes, most patients eventually experience disease progression and receive subsequent therapies.5,6,7,8

About HER3

HER3 is a member of the HER family of receptor tyrosine kinases.11 It is estimated that about 83% of primary NSCLC tumors and 90% of advanced EGFR-mutated tumors express HER3 after prior EGFR TKI treatment.12 HER3 is associated with poor treatment outcomes, including shorter relapse-free survival and significantly reduced survival.13,14 There is currently no HER3 directed therapy approved for the treatment of any cancer.

About Patritumab Deruxtecan

Patritumab deruxtecan (HER3-DXd) is an investigational HER3 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, patritumab deruxtecan is composed of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

About the Patritumab Deruxtecan Clinical Development Program

A comprehensive global clinical development program is underway evaluating the efficacy and safety of patritumab deruxtecan across cancers. Trials in combination with other anticancer treatments are also underway.

Syndax Announces Participation in June Investor Conferences

On May 29, 2025 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, reported that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences (Press release, Syndax, MAY 29, 2025, View Source [SID1234653489]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.
Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company’s website at www.syndax.com, where a replay will also be available for a limited time.

Immuneering to Present at the Jefferies Global Healthcare Conference

On May 29, 2025 Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, reported that management will present at the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 4-5, 2025, to discuss the company’s pipeline, platform, and business strategy (Press release, Immuneering, MAY 29, 2025, View Source [SID1234653488]). Participating will be Ben Zeskind, Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Brett Hall, Chief Scientific Officer, Harold "E.B." Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Format: Company Presentation and 1×1 Investor Meetings

Date/Time: June 5 from 12:50 – 1:20 pm ET

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

On May 29, 2025 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, reported that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET (Press release, Replimune, MAY 29, 2025, View Source [SID1234653487]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.

GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio

On May 29, 2025 GSK plc (LSE/NYSE: GSK) reported that new data across the oncology pipeline and portfolio will be presented in more than 60 abstracts at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (30 May – 3 June) in Chicago, IL and the 30th European Hematology Association (EHA) (Free EHA Whitepaper) Congress (12 – 15 June) in Milan, Italy (Press release, GlaxoSmithKline, MAY 29, 2025, View Source [SID1234653486]). These results highlight GSK’s research and development programmes which aim to improve outcomes for patients with blood cancers, gynaecologic cancers and other solid tumours through innovative therapeutic approaches.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reinforcing the potential for belantamab mafodotin to redefine treatment of relapsed/refractory multiple myeloma
At ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper), GSK will share updated data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) programme. Key presentations include:

Updated progression-free survival (PFS) analysis from the DREAMM-8 study (EHA abstract #PF728).
DREAMM-8 data shows the association of measurable residual disease (MRD) negativity with efficacy endpoints (ASCO abstract #7515).
First presentation of safety and efficacy data from DREAMM-20 evaluating the unconjugated monoclonal antibody, belantamab. This represents an important first step towards exploring next-generation BCMA solutions (ASCO abstract #7550).
A new analysis from DREAMM-7 and DREAMM-8 which contextualise manageability of eye-related side effects including impact on reading and driving (EHA abstract #PS1761).
Importance of starting treatment early with momelotinib which may impact survival in myelofibrosis patients
At EHA (Free EHA Whitepaper) 2025, new analyses from the pivotal MOMENTUM and SIMPLIFY-1 trials reinforce momelotinib as a standard of care in myelofibrosis (MF), The data explore the benefits of initiating treatment for myelofibrosis earlier, which could lead to better outcomes for patients. Presentations include:

New post-hoc analyses from the MOMENTUM & SIMPLIFY-1 trials show addressing anaemia and achieving haemoglobin improvement of 10 g/dL or above may positively impact overall survival (EHA abstract #PF828).
New SIMPLIFY-1 subgroup data show the impact of patients achieving both ≥ 35% spleen volume reduction (SVR35) and transfusion independence responses with momelotinib, which are prioritised in treatment guidelines to support optimal long-term outcomes in patients (EHA abstract #PS1829).
Understanding the impact of our medicines on quality of life for patients with gynaecologic cancers
Findings from GSK’s gynaecologic cancer portfolio focus on understanding the patient treatment experience to better inform GSK’s research efforts and clinical care. These include:

Results of the phase III FIRST-ENGOT-OV44 trial provides insight on the role of adding dostarlimab to platinum-based chemotherapy followed by niraparib maintenance, with or without bevacizumab, in first-line advanced ovarian cancer (ASCO abstract #LBA5506).
Patient reported outcomes from the phase III PRIMA trial (ENGOT-OV26/GOG-3012) will help inform healthcare providers on the impact of disease progression on quality of life in patients with newly diagnosed advanced ovarian cancer (ASCO abstract #5551).
New post-hoc analysis from Part 1 of the phase III RUBY trial (EN6-NSGO/GOG-3031) evaluates time to changes in quality of life with dostarlimab plus chemotherapy (carboplatin-paclitaxel) compared to chemotherapy alone in patients with primary advanced or recurrent endometrial cancer (ASCO abstract #5600).
Full list of GSK’s presentations at ASCO (Free ASCO Whitepaper):
Belantamab Mafodotin

Abstract Name Presenter Presentation Details
Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial

S. Trudel

Rapid Oral Abstract Session, #7515

Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial

S. Kaptanis

Poster Session, #7550

DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features

S. Trudel

Poster Session, #7533

Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data

M. Purser

Poster Session, #7536

Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf)

E. Manasanch

Poster Session, #7544

DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features

S. Roy-Ghanta

Poster Session, #7546

Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials

M. Pitombeira de Lacerda

Poster Session, #7548

Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM)

S. Lonial

Poster Session, TPS7567

Dostarlimab

Abstract Name Presenter Presentation Details
Time to quality of life (QoL) improvement or deterioration in patients (pts) with primary advanced or recurrent endometrial cancer (pA/R EC) treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Z. Novak

Poster Session, #5600

Molecular testing in primary advanced or recurrent endometrial cancer: a cost-effectiveness analysis

Y. Chen

Poster Session, #5598

Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

C. Matthews

Poster Session, #5601

The role of platinum-free interval in advanced endometrial cancer treatment: A real-world study of 843 patients

J. Chan

Poster Session, #5609

AZUR-4, a phase 2, open label, randomized study of neoadjuvant dostarlimab plus capecitabine plus oxaliplatin (CAPEOX) versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer

G. Rasschaert

Poster Session, TPS3649

Niraparib

Abstract Name Presenter Presentation Details
FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC)

A. Hardy-Bessard

Oral Abstract Session, LBA5506

Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC)

M. Shahin

Poster Session, #5551

A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors

V. Samnotra

Poster Session, TPS3174

First public and private ovarian cancer register in Chile: Potential effect of national formulary inclusion and COVID-19 pandemic on survival outcomes

C. Ibanez

Online publication, #e17586

First report on the characterization of public and private patients with ovarian cancer in Chile

C. Ibanez

Online publication, #e17588

Full list of Alliance, investigator-initiated studies and supported collaborative studies at ASCO (Free ASCO Whitepaper):

Abstract Name Presenter Presentation Details
Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial

E. Terpos

Rapid Oral Abstract Session, #7512

Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis

M. Mooradian

Oral Abstract Session, LBA9504

Niraparib plus PD-1 inhibitor for patients previously treated with immune checkpoint inhibitor for solid tumors with homologous recombination repair gene mutation (IMAGENE): A phase II basket study

T. Kato

Poster Session, #2613

A phase 1 study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: Dose-expansion results from the NiraPim (EPOC2102) study

Y. Kawamoto

Poster Session, #3079

Cobolimab and dostarlimab in the first-line treatment of unresectable hepatoma: A multi-center, single arm, phase 2 trial

J. Acoba

Poster Session, #4099

Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance

P. Soberanis Pina

Poster Session, #5561

Biomarker results from the KGOG3056/NIRVANA-R trial: Maintenance niraparib plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor

H. Cho

Poster Session, #5556

Quality of life and lifestyle changes during and after therapy in women with endometrial cancer: A global study of 1,066 patients (NOGGO, ENGOT, GCIG, ENGAGe-IMPROVE/EXPRESSION XI)

L. Chinczweski

Poster Session, #5606

Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM)

R. Galot

Poster Session, #6028

IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast

D. Cescon

Poster Session, TPS1121

A global phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma

N. Sanai

Poster Session, TPS2096

Safety and tolerability of dostarlimab in combination antiretroviral therapy refractory HIV-associated Kaposi Sarcoma: preliminary results from the StarKap phase Ib trial

C. Fulgenzi

Online publication, #e14588

A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive and HER2 negative breast cancer

H. Ohm

Online publication, #e12598

PROMIS scores of cancer survivors in the Comprehensive Outcomes for After Cancer Health (COACH) study: An interim analysis

M. Hammer

Online publication, #e23182

Full list of GSK presentations at EHA (Free EHA Whitepaper):
Belantamab Mafodotin

Abstract Name Presenter Presentation Details
Efficacy and safety outcomes in patients (pts) with renal impairment in the Phase 3 DREAMM-7 and DREAMM-8 trials

M. Pitombeira de LaCerda

Poster Session #PF701

DREAMM-8: Minimal residual disease negativity in patients with relapsed/refractory multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone vs standard-of-care regimen

M. Dimopoulos

Poster Session, #PF726

Updated results from phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

M. Dimopoulos

Poster Session, #PF728

DREAMM-7 study of belantamab mafodotin + bortezomib + dexamethasone vs daratumumab + bortezomib + dexamethasone in relapsed/refractory multiple myeloma: a high-risk cytogenetic subgroup analysis

M. Mateos

Poster Session, #PF739

DREAMM-8 study of belantamab mafodotin + pomalidomide + dexamethasone vs pomalidomide + bortezomib + dexamethasone in relapsed/refractory multiple myeloma: a high-risk cytogenetic subgroup analysis

M. Dimopoulos

Poster Session, #PF741

Baseline ocular conditions and incidence of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf)

M.Dimopoulos

Poster Session, #PF759

European clinical views on the challenges of treating patients with autologous chimeric antigen receptor t-cell therapy and bispecific antibodies in multiple myeloma

M. Purser

Poster Session, # PF760

Belantamab for the treatment of multiple myeloma: results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial

H. Quach

Poster Session, #PF783

Belantamab mafodotin treatment triggers immunologic and inflammatory cell death in myeloma, with implications for the tumour microenvironment and duration of response

E. Watson

Poster Session: #PS1685

DREAMM-7 study of belantamab mafodotin + bortezomib + dexamethasone vs daratumumab + bortezomib + dexamethasone in relapsed/refractory multiple myeloma: efficacy in patients by subsequent therapy

V. Hungria

Poster Session, #PS1734

Real-world effectiveness and safety of belantamab mafodotin (belamaf) monotherapy in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated in Europe

M. Cavo

Poster Session, #PS1741

Characterization of ophthalmic examination findings (OEFs) and impact on reading and driving in patients with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin (belamaf)

R. Hajek

Poster Session, #PS1761

Characterization of infections in patients with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin (belamaf)-based regimens from DREAMM-7 and DREAMM-8 trials

P. Robak

Poster Session, #PS1762

Real-world ocular monitoring and safety of belantamab mafodotin (belamaf) monotherapy in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated in Europe and the US

F. Schjesvold

Poster Session, #PS1771

Phase 3 DREAMM-10 study design: belantamab mafodotin plus lenalidomide and dexamethasone vs daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly-diagnosed multiple myeloma

M. Dimopoulos

Poster Session: #PS1793

Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: an indirect comparison using patient-level data

M Beksac

Online publication, #PB2895

Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Analysis of the China subpopulation in the DREAMM-7 study

C. Fu

Online publication, #PB2935

Clinical outcomes of relapsed or refractory multiple myeloma overall and among lenalidomide-refractory patients in East Asia: A targeted literature review

Y. Tao

Online publication, #PB2969

Treatment Patterns and Outcomes in Multiple Myeloma: A Retrospective Analysis of Clinical and Demographic Characteristics in Argentina and Brazil (2018-2024)

V Hungria

Online publication, #PB2911

Treatment patterns at first relapse and their outcomes in multiple myeloma; a Finnish RWD study

J Lievonen

Online publication, #PB2936

Momelotinib

Abstract Name Presenter Presentation Details
Survival impact and kinetics of hemoglobin improvement with momelotinib in patients with myelofibrosis and moderate to severe anemia: post hoc analyses of SIMPLIFY-1 and MOMENTUM

F. Palandri

Poster Session, #PF828

Impact of dual spleen response and transfusion independence on survival in JAK inhibitor–naive patients with myelofibrosis and anemia treated with momelotinib: a subgroup analysis of SIMPLIFY-1

F. Palandri

Poster Session, #PS1829

The economic burden of myelofibrosis treated with ruxolitinib in France

J. Kiladijian

Poster Session, #PS1844

Trial in progress: MIDAS – a phase 2, randomized, open-label study of momelotinib in patients with anemia due to lower-risk myelodysplastic syndromes

G. Garcia-Manero

Online publication, #PB2773

Clinical determinants of health-related quality of life in patients with Janus Kinase Inhibitor–experienced myelofibrosis

S. Conlon

Online publication, #PB3083

Full list of Alliance, investigator-initiated studies and supported collaborative studies at EHA (Free EHA Whitepaper):

Abstract Name Presenter Presentation Details
Interim analysis of MRD-guided maintenance therapy with belantamab mafodotin and lenalidomide after auto-HCT in newly diagnosed multiple myeloma

Y. Aljawai

Poster Session, #PF754

Real-world treatment patterns and clinical outcomes of relapsed/refractory multiple myeloma in Asia – an Asian myeloma network study

C. Soekojo

Poster Session: #PF760

Evaluation of a Novel Patient-Reported Tool Guiding Extended Dosing Schedule of Belantamab Mafodotin in Combination with Lenalidomide and Dexamethasone in Newly Diagnosed Mutiple Myeloma Patients; Updated Ophthalmic Safety from a Phase 1/2 Trial of the Greek Myeloma Study Group

E.Terpos

Poster: #PS1769

Extended dosing schedule of Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: The Phase 1/2 BelaDRd Study

E. Terpos

Poster: #PF733

Real-World Clinical Practice in Italian Patients with Multiple Myeloma: Preliminary Analysis of the MY MYELOMA Multicenter Registry

G. Bertuglia

Poster: #PF775

A Multicenter Phase 2 Study Designed to Optimized the Schedule of Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

T Popková

Poster: #PF734

About multiple myeloma
Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.1,2 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year.3 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments.4 Many patients with multiple myeloma are treated in a community cancer setting, leaving an urgent need for new, effective therapies with manageable side effects that can be administered outside of an academic centre.5,6

About myelofibrosis
Myelofibrosis is a rare blood cancer that disrupts the body’s normal production of blood cells because of dysregulated JAK-signal transducer and activator of transcription protein signalling. The clinical hallmarks of myelofibrosis are splenomegaly (enlarged spleen), severely low blood counts, including anaemia and thrombocytopenia, and debilitating constitutional symptoms, such as fatigue, night sweats and bone pain, attributable to ineffective haematopoiesis and excessive production of proinflammatory cytokines.7,8

About ovarian cancer
Ovarian cancer is the eighth most common cancer in women worldwide.9 Despite high response rates to platinum-based chemotherapy in the first-line setting, approximately 85% of patients will experience disease recurrence. Once the disease recurs, it is rarely curable, with decreasing time intervals to each subsequent recurrence.10

About endometrial cancer
Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. Endometrial cancer is the most common gynaecologic cancer in developed countries,11 with an estimated 1.6 million people living with active disease at any stage and 417,000 new cases reported each year worldwide.16 Incidence rates are expected to rise by approximately 40% between 2020 and 2040.12 In Europe, approximately 121,000 people are estimated to be diagnosed with primary advanced or recurrent endometrial cancer each year.13 Approximately 15-20% of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.14 Among patients with primary advanced or recurrent endometrial cancer, approximately 75% have MMRp/MSS tumours.15

About dMMR/MSI-H rectal cancer
Rectal cancer is a form of cancer that starts in the rectum, the final section of the large intestine, and is often categorised as part of a group of cancers called colorectal cancer. Colorectal cancer is the third most commonly diagnosed cancer in the world.16 In the US, it is estimated that approximately 46,220 individuals are diagnosed annually with rectal cancer.17 Approximately 5-10% of all rectal cancers are dMMR/MSI-H, meaning that they contain abnormalities that affect the proper repair of DNA when copied in a cell.18 Mismatch repair deficient status is a biomarker that has been shown to predict response to immune checkpoint blockade with PD-1 therapy.19,20 Tumours with this biomarker are most commonly found in endometrial, colorectal and other gastrointestinal cancers but may also be found in other solid tumours.21,22,23,24

About glioblastoma
Glioblastoma is a type of cancer that starts as a growth of cells in the brain or spinal cord. It grows quickly and can invade and destroy healthy tissue.25 It accounts for more than half of all primary malignant brain tumours and is one of the most complex and treatment-resistant cancers, resulting in poor patient outcomes.26 Survival rates and mortality statistics for glioblastoma have been virtually unchanged for decades, highlighting the need to investigate new treatment options.26

About Blenrep (belantamab mafodotin)
Belantamab mafodotin is an ADC comprising a humanised BCMA monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; the monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa Inc., a member of the Kyowa Kirin Group.

In April 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) licensed belantamab mafodotin combinations for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least one prior therapy. In May 2025, the Japan Ministry of Health, Labour and Welfare approved belantamab mafodotin for the treatment of adults with relapsed or refractory multiple myeloma.

Important information for belantamab mafodotin in the United Kingdom
Indication

In the UK, belantamab mafodotin is indicated in adults for the treatment of multiple myeloma:

in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.
IMPORTANT SAFETY INFORMATION FOR BLENREP
More information can be found in the Blenrep Summary of Product Characteristics and Patient Information leaflets available on the MHRA Products website.

About Omjjara (momelotinib)
Momelotinib has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1).27,28,29,30 Inhibition of JAK1 and JAK2 may improve constitutional symptoms and splenomegaly.27,28,30 Additionally, inhibition of ACVR1 leads to a decrease in circulating hepcidin levels, potentially contributing to anaemia-related benefit.27,28,29,30

In September 2023, the US Food and Drug Administration licensed31 momelotinib under the brand name Ojjaara for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythemia), in adults with anaemia.

In January 2024, the European Commission granted marketing authorisation32 for momelotinib for disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythemia myelofibrosis and who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. Momelotinib was also approved33 by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom to treat the symptoms experienced by adult myelofibrosis patients who have moderate or severe anaemia.

In June 2024, the Japan Ministry of Health, Labour and Welfare (MHLW) approved34 momelotinib for the treatment of myelofibrosis.

Important information for momelotinib in the EU
Indication

Momelotinib is indicated for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

Refer to the Omjjara EMA Reference Information for a full list of adverse events and the complete important safety information in the EU.

About Zejula (niraparib)
Niraparib is an oral, once-daily Poly (ADP-ribose) polymerase (PARP) inhibitor indicated in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy; and for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy and who have been selected based on a US FDA-approved companion diagnostic for niraparib.

Important information for niraparib in the EU
Indication

Niraparib is indicated:

as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Refer to the Zejula EMA Reference Information for a full list of adverse events and the complete important safety information in the EU.

About Jemperli (dostarlimab)
Dostarlimab, a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK’s ongoing immuno-oncology-based research and development programme. A robust clinical trial programme includes studies of dostarlimab alone and in combination with other therapies in gynaecologic, colorectal and lung cancers, as well as where there are opportunities for transformational outcomes.

In the US, dostarlimab is indicated in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This includes patients with MMRp/MSS and dMMR/MSI-H tumours. Dostarlimab is also approved as a single agent for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. Additionally, dostarlimab is indicated in the US for patients with dMMR recurrent or advanced solid tumours, as determined by a US FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. The latter indication is approved in the US under accelerated approval based on tumour response rate and durability of response. Continued approval for this indication in solid tumours may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 

Dostarlimab was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a collaboration and exclusive license agreement signed in March 2014. Under this agreement, GSK is responsible for the ongoing research, development, commercialisation, and manufacturing of dostarlimab and cobolimab (GSK4069889), a TIM-3 antagonist. 

Important information for dostarlimab in the EU
Indication

Dostarlimab is indicated:

in combination with carboplatin and paclitaxel, for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy;
as monotherapy for treating adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
Refer to the Jemperli EMA Reference Information for a full list of adverse events and the complete important safety information in the EU.